2-(9-octadecenyloxy)ethanol | 94677-31-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(9-octadecenyloxy)ethanol
• 英文别名: 2-octadec-9-enoxyethanol
• CAS: 94677-31-3
• 化学式: C₂₀H₄₀O₂
• 分子量: 312.536
• InChiKey: KWVPFECTOKLOBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  22
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(9-octadecenyloxy)ethanol 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 12.5h， 生成 2-{2-[((E)-Octadec-9-enyl)oxy]-ethoxy}-[1,3,2]dioxaphospholane 2-oxide
  参考文献：
  名称：

  A new efficient and versatile synthesis of alkyl prosphorylcholines

  摘要：

  DOI：

  10.1016/s0040-4039(00)98424-7

文献信息

• Preparation Method for Amide Compounds and Use Thereof in Medical Field
  申请人：Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

  公开号：US20220024941A1

  公开（公告）日：2022-01-27

  Provided are a preparation method for amide compounds and use thereof in medical field. Specifically, provided are small molecule amide compounds. Such compounds are inhibitors of enhancer homolog 2 (EZH2) of Zeste gene, and can be used for preventing and/or treating related diseases mediated by EZH2, including tumors, myeloproliferative diseases or autoimmune diseases.

  提供了一种酰胺化合物的制备方法及其在医学领域中的用途。具体来说，提供了小分子酰胺化合物。这些化合物是Zeste基因的增强子同源物2（EZH2）的抑制剂，可用于预防和/或治疗由EZH2介导的相关疾病，包括肿瘤、骨髓增生性疾病或自身免疫疾病。
• CHROMENE COMPOUND, CURABLE COMPOSITION COMPRISING THE COMPOUND, AND OPTICAL ARTICLE INCLUDING A CURED BODY OF THE CURABLE COMPOSITION
  申请人：TOKUYAMA CORPORATION

  公开号：US20200190106A1

  公开（公告）日：2020-06-18

  A chromene compound having at least one indenonaphthopyran moiety which has a group forming a spiro ring together with the 13-position carbon atom and further an oligomer chain group selected from a polyalkylene oxide oligomer chain group having at least three recurring units and a polyester oligomer chain group having at least three recurring units, represented by the following formula and having reduced matrix dependence: wherein R 1 and R 2 are each a group which may have an oligomer chain group, the ring Z bonded to the 13-position carbon atom of the chromene compound is a Spiro ring group, and R 3 and R 4 are each an aryl group or heteroaryl group which may have an oligomer chain group. Preferably, the chromene compound has at least one oligomer chain group in the molecule.

  具有至少一个印苯并萘吡喃基团的色酮化合物，其中该基团与13位碳原子形成螺环，并且进一步具有从至少三个重复单元中选择的聚烷氧基寡聚物链基团和聚酯寡聚物链基团中的一个寡聚物链基团，由下式表示并具有降低的矩阵依赖性： 其中R1和R2是各自可能具有寡聚物链基团的基团，与色酮化合物的13位碳原子键合的环Z是螺环基团，而R3和R4是各自可能具有寡聚物链基团的芳基或杂环基团。最好，该色酮化合物在分子中至少具有一个寡聚物链基团。
• CARRIER FOR NEGATIVELY CHARGED DRUGS COMPRISING A CATIONIC LIPID AND A PREPARATION METHOD THEREOF
  申请人：Choi Sung-Won

  公开号：US20130266641A1

  公开（公告）日：2013-10-10

  Disclosed are a carrier for delivering a negatively charged drug, comprising a cationic lipid represented by formula 1, and a preparation method thereof. Also disclosed is a pharmaceutical composition comprising a negatively charged drug and a cationic lipid represented by formula 1, wherein the negatively charged drug forms a complex with the cationic lipid. The composition can increase the in vivo stability of the negatively charged drug after local or systemic administration and allows the intracellular delivery of the negatively charged drug. Thus, the composition will be useful for improving the therapeutic effect of the negatively charged drug.

  本发明公开了一种用于传递负电药物的载体，包括由公式1表示的阳离子脂质以及其制备方法。还公开了一种药物组合物，包括由公式1表示的阳离子脂质和负电药物，其中负电药物与阳离子脂质形成复合物。该组合物可以增加局部或全身给药后负电药物的体内稳定性，并允许负电药物的细胞内传递。因此，该组合物对于提高负电药物的治疗效果将是有用的。
• PHOTOCHROMIC COMPOSITION
  申请人：TOKUYAMA CORPORATION

  公开号：US20160222285A1

  公开（公告）日：2016-08-04

  A photochromic composition comprising (A) a polyrotaxane having a composite molecular structure composed of an axial molecule and a plurality of cyclic molecules clathrating the axial molecule and (B) a photochromic compound.

  一种光致变色组合物，包括(A)聚轮烷，其具有由轴向分子和多个环状分子组成的复合分子结构，并且(B)光致变色化合物。
• Process for polymerizing formaldehyde
  申请人：UBE INDUSTRIES, LTD.

  公开号：EP0026047A1

  公开（公告）日：1981-04-01

  Undesirable deposition of polyoxymethylene onto the inner wall of a polymerization vessel and onto a stirrer, which deposition is observed in the slurry polymerization of formaldehyde carried out in an inert organic liquid medium in the presence of a polymerization catalyst, can be minimized by carrying out the slurry polymerization in the presence of at least one polyvalent metal salt selected from polyvalent metal salts of alkylsalicylic acids and polyvalent metal salts of dialkyl esters of sulfosuccinic acid. Optionally, a polyethylene glycol monoether may be used in addition to the polyvalent metal salt.

  在惰性有机液体介质中，在聚合催化剂存在下进行甲醛淤浆聚合时，会观察到聚甲醛在聚合容器内壁和搅拌器上有不理想的沉积，通过在至少一种多价金属盐（选自烷基水杨酸多价金属盐和磺基丁二酸二烷基酯多价金属盐）存在下进行淤浆聚合，可将聚甲醛在聚合容器内壁和搅拌器上的不理想沉积降至最低。 除多价金属盐外，还可选择使用聚乙二醇单醚。